Award
National Institute of Allergy and Infectious Diseases 5U01AI172853-04
Development of a Novel Therapeutic for Mitigating Radiation-Induced Microbiome Dysbiosis and Acute Gastrointestinal Syndrome
Recipient
Columbia University Health Sciences, New York, NY, United States
Award Amount
$495,545.00
Ceiling
$495,545.00
Awarded
January 09, 2026
Identifier
5U01AI172853-04
This NIH-funded project supports the development of MIIST305, a novel therapeutic to protect the gastrointestinal tract from radiation-induced injury by maintaining gut microbiota balance and reducing inflammation, with the goal of FDA approval for use in radiation public health emergencies.
Description
Development of a novel GI-targeted therapeutic drug (MIIST305) to mitigate radiation-induced gastrointestinal syndrome characterized by microbiome dysbiosis, mucosal layer destruction, intestinal epithelial barrier dysfunction, and inflammation, aiming for FDA approval as a medical countermeasure.